Harnessing Immune Response in Acute Myeloid Leukemia

Area of Science:

• Hematology
• Immunotherapy
• Oncology

Background:

• Conventional chemotherapy and targeted therapies offer limited survival benefits for relapsed/refractory (R/R) acute myeloid leukemia (AML).
• Cellular therapy has demonstrated success in other hematological malignancies, with approved products available.
• There is a significant unmet need for effective treatments in R/R AML, particularly for elderly or unfit patients.

Purpose of the Study:

• To review recent clinical research on cellular therapy for AML.
• To explore various cellular therapy approaches, from established methods to novel adoptive immunotherapies.
• To highlight the potential of cellular therapy as an alternative to allogeneic hematopoietic stem cell transplantation.

Main Methods:

• Review of current clinical research and literature on cellular therapy in AML.
• Discussion of established cellular therapy approaches, including donor lymphocyte infusions.
• Analysis of modern adoptive immunotherapies such as alloreactive NK cells, CAR-T, and CAR-NK cells, and T/NK cell engaging platforms (BiTEs, DARTs, ANKET™).

Main Results:

• Cellular therapy, including engineered T and NK cells, is under active investigation for R/R AML.
• Early data suggests potential efficacy and safety for various cellular therapy modalities in AML.
• No cellular therapy products are currently approved for R/R AML, indicating an area for further development.

Conclusions:

• Cellular therapy represents a promising frontier for R/R AML treatment, offering potential alternatives for patients ineligible for stem cell transplantation.
• Ongoing research into engineered T and NK cells, and novel engaging platforms, is crucial for advancing AML therapy.
• Further clinical trials are needed to establish the efficacy and safety of these innovative cellular therapies in AML.